These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21099368)

  • 1. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.
    Liu G; Dou S; Baker S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
    Cancer Biol Ther; 2010 Oct; 10(8):767-74. PubMed ID: 21099368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.
    Liu G; Dou S; Pretorius PH; Liu X; Chen L; Rusckowski M; Hnatowich DJ
    Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):333-40. PubMed ID: 20639818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.
    Liu G; Dou S; He J; Liu X; Rusckowski M; Hnatowich DJ
    Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):237-46. PubMed ID: 17021815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretargeting the masses: a means of improving and mainstreaming targeted molecular delivery?
    Nguyen V; Conyers JM; Mintz A
    Cancer Biol Ther; 2010 Oct; 10(8):775-9. PubMed ID: 20935465
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting.
    Chen X; Dou S; Liu G; Liu X; Wang Y; Chen L; Rusckowski M; Hnatowich DJ
    Bioconjug Chem; 2008 Aug; 19(8):1518-25. PubMed ID: 18646837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue.
    Liu G; Dou S; Mardirossian G; He J; Zhang S; Liu X; Rusckowski M; Hnatowich DJ
    Clin Cancer Res; 2006 Aug; 12(16):4958-64. PubMed ID: 16914585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.
    Liu G; He J; Dou S; Gupta S; Vanderheyden JL; Rusckowski M; Hnatowich DJ
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):417-24. PubMed ID: 14691611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An improved method for covalently conjugating morpholino oligomers to antitumor antibodies.
    He J; Liu G; Dou S; Gupta S; Rusckowski M; Hnatowich D
    Bioconjug Chem; 2007; 18(3):983-8. PubMed ID: 17385902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
    He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
    J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF.
    He J; Wang Y; Dou S; Liu X; Zhang S; Liu G; Hnatowich D
    Mol Pharm; 2010 Aug; 7(4):1118-24. PubMed ID: 20507096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.
    Liu G; He J; Dou S; Gupta S; Rusckowski M; Hnatowich DJ
    Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1115-23. PubMed ID: 16133391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog.
    Liu G; Mang'era K; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
    J Nucl Med; 2002 Mar; 43(3):384-91. PubMed ID: 11884499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.
    Liu G; Dou S; Pretorius PH; Liu X; Rusckowski M; Hnatowich DJ
    Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):272-80. PubMed ID: 17909792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector.
    Liu G; Dou S; Rusckowski M; Hnatowich DJ
    Mol Cancer Ther; 2008 May; 7(5):1025-32. PubMed ID: 18483292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigations of 99mTc morpholino pretargeting in mice.
    Liu G; Liu C; Zhang S; He J; Liu N; Gupta S; Rusckowski M; Hnatowich DJ
    Nucl Med Commun; 2003 Jun; 24(6):697-705. PubMed ID: 12766607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.
    Liu G; Dou S; Chen X; Chen L; Liu X; Rusckowski M; Hnatowich DJ
    Cancer Biother Radiopharm; 2010 Dec; 25(6):757-62. PubMed ID: 21204772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.
    Liu G; Dou S; Liu Y; Wang Y; Rusckowski M; Hnatowich DJ
    Bioconjug Chem; 2011 Dec; 22(12):2539-45. PubMed ID: 21985267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting.
    Liu G; Dou S; He J; Yin D; Gupta S; Zhang S; Wang Y; Rusckowski M; Hnatowich DJ
    Appl Radiat Isot; 2006 Sep; 64(9):971-8. PubMed ID: 16730997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation.
    Liu G; Cheng D; Dou S; Chen X; Liang M; Pretorius PH; Rusckowski M; Hnatowich DJ
    Mol Imaging Biol; 2009; 11(5):303-7. PubMed ID: 19326173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy.
    Dou S; Smith M; Wang Y; Rusckowski M; Liu G
    Cancer Biother Radiopharm; 2013 May; 28(4):335-42. PubMed ID: 23469942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.